{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-057233","form_type":"8-K","ticker":"HOTH","cik":"0001711786","company_name":"Hoth Therapeutics, Inc.","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.434071+00:00","generated_at":"2026-05-18T22:45:44.240289+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Hoth Therapeutics reports 100% efficacy in Phase 2a of HT-001 for EGFRI skin toxicities","bullets":["Phase 2a CLEER-001 study: 100% of patients achieved primary endpoint; 66% reported reduced pain/itching.","All patients maintained EGFR inhibitor dosage while on HT-001, preserving cancer treatment.","Preclinical data showed 56% reduction in hair loss and 58% reduction in facial lesions with preventive HT-001.","HT-001 uses 505(b)(2) pathway; IND open; NDA submission targeted for 2030.","No FDA-approved therapy exists for EGFRI-induced cutaneous toxicities; HT-001 seeks first-in-market."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-057233","json":"https://secwatch.observer/filing/0001213900-25-057233.json","markdown":"https://secwatch.observer/filing/0001213900-25-057233.md","text":"https://secwatch.observer/filing/0001213900-25-057233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711786/000121390025057233/0001213900-25-057233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711786/000121390025057233/ea0246748-8k_hoth.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T22:45:44.240289+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}